Skip to content

Confirm, characterise, then decide: J's CLL

A living knowledge base, last updated 7 October 2026. Prepared for J (Skåne), who was told on 5 October 2026 that two excised lymph nodes showed KLL (kronisk lymfatisk leukemi, chronic lymphocytic leukaemia, CLL).

Not medical advice

This knowledge base is compiled from published sources and has not been reviewed by a physician. It exists to help J and the people around him prepare for conversations with his care team. Every decision about tests and treatment belongs with his doctors.

J's most valuable work in the coming weeks is not choosing a drug but pinning down the diagnosis, the stage and the biology of his disease, because those three facts decide everything else. In Sweden about 85% of people with KLL need no treatment when they are diagnosed, roughly one in three never does, and decades of randomised trials, most recently CLL12 with ibrutinib, show that treating before the international (iwCLL) criteria are met delays progression but has never prolonged survival in any risk group (Nationellt vårdprogram KLL v8.2, ch. 10; CLL12 final analysis, JCO 2025). His diagnosis came from excised lymph nodes rather than the usual blood test (73% of Swedish patients in 2020–2024 were diagnosed on blood alone), so the pathology report must be read together with blood flow cytometry to settle whether this is CLL or its nodal form SLL and to confirm there is no transformation or look-alike lymphoma (KLL registry report 2025). If treatment is ever needed, two tests, TP53 (FISH plus sequencing) and IGHV, shape the menu: the Swedish guideline (version 8.2, January 2026) recommends fixed-duration venetoclax-obinutuzumab for 12 months or acalabrutinib-venetoclax for 14 months when TP53 is intact, and continuous second-generation BTK inhibition when it is not (vårdprogram §11.2). Swedish law (Patientlagen 8 kap. 1 §) gives him a second-opinion route paid by Region Skåne, travel included if the referral is marked correctly; at SUS Lund, Daniel Roth represents Region Syd in the national KLL guideline group and the KLL registry steering group, and Oscar Lindblad is an adjunct co-author of guideline version 8.2 and Lund's site contact for the CLL18 trial, whereas Mats Jerkeman is a leading lymphoma oncologist with no CLL-specific role, and the deepest Swedish CLL research footprint is at Karolinska and Uppsala (Patientlag 2014:821; vårdprogram ch. 25; KLL registry report 2025; CTIS CLL18). KLL is a cancer, usually lifelong, and infection contributes to a quarter to half of CLL deaths, yet outcomes have improved sharply: in Sweden, five-year relative survival after starting treatment rose from 57% (2007–2011) to 84% (2020–2024). These are group averages, not a forecast for J, whose age, blood counts, stage and biology are not yet known to us (KLL registry report 2025).

No country has been shown to have clearly better CLL survival than Sweden. If cost and travel are no obstacle, going abroad adds most as a one-off expert opinion in unusual or high-risk disease and, later, after relapse on both drug classes or in Richter transformation (World-class options abroad).

How to read these pages. Labels: [E] = established (stated by a statute, regulator, guideline, trial publication or registry report); [I] = inference (reasoning from cited facts); [S] = speculation. Source flags: abstract only, conference/secondary (congress data seen through news or review articles), press release, archived copy (the link goes to an archived copy of the web page), unconfirmed (not confirmed on an official page). "VP8.2" means the Swedish national KLL care programme, Nationellt vårdprogram kronisk lymfatisk leukemi, version 8.2, adopted 27 January 2026.

Start with these

J's situation

Understanding CLL

  • The diagnosis — CLL, SLL and MBL; what the pathology report should contain; when expert review is warranted.
  • Tests and work-up — what is needed at diagnosis, before treatment, and only in selected cases.
  • Does he need treatment now? — the seven iwCLL criteria, and why early treatment has not improved survival.
  • Molecular risk profile — TP53, IGHV and other markers, prognostic versus predictive.
  • Prognosis — Swedish registry survival, prognostic scores, and what an individual estimate would need.
  • Richter transformation — the risk in perspective, warning signs, diagnosis and treatment.

Treatment

  • Treatment landscape 2026 — fixed-duration versus continuous therapy; EU approval, Swedish reimbursement and guideline preference; relapse.
  • Trial evidence — CLL14, CLL13, CLL17, AMPLIFY and the other landmark trials.
  • Treatment decision matrix — the evidence by situation: TP53, IGHV, fitness, kidneys, heart, preference.

Living with CLL

Care in Sweden and abroad

  • Second opinion — the legal right in Patientlagen ch. 8, costs, and a step-by-step process.
  • Specialists and centres — verified Swedish CLL specialists, and when international expertise matters.
  • World-class options abroad — the world's leading CLL experts and centres, remote second opinions open to Swedish residents, treatments and trials abroad, and when travelling actually helps.
  • Lund in depth — how CLL care, pathology, genetics and trials work at Skåne University Hospital.
  • Clinical trials — recruiting trials relevant to J in Sweden and nearby Copenhagen.

Evidence and audit